Brian Shields: Pfizer’s CROWN study was a highlight of ASCO24

Brian Shields, Creator of KOL Pulse AI, shared on LinkedIn:

“Pfizer’s CROWN study was a highlight of ASCO24.

How should Oncologists interpret the data?

Can Artificial Intelligence Help? Here’s feedback from KOL Pulse AI regarding the following question (sorry for my typos, luckily, AI figured out what I was asking):

Regarding the key opinion leader concerns of the CROWN trial, please always share the source link to your data.

Based on the provided context, there are a few key opinion leader concerns regarding the CROWN trial results for lorlatinib in ALK-positive non-small cell lung cancer:

Toxicity: Tom Newsom-Davis notes that ‘Toxicity [is the] main issue’ with lorlatinib treatment.

Efficacy in TP53 co-mutations: Dr. Newsom-Davis also mentions ‘TP53 co-mut still do less well’, indicating concerns about efficacy in patients with TP53 co-mutations.

First-line use vs. sequential therapy: Alfredo Addeo expresses uncertainty about using lorlatinib first-line in all patients, stating ‘Would I use it in 1st line all the time?

I don’t think I would but happy to change my mind if data and prestation are really really [compelling].’

Lack of head-to-head comparison with alectinib: H. Jack West suggests that comparing lorlatinib directly to alectinib (rather than crizotinib) may have been more informative, stating ‘If shown to soundly beat alectinib H2H, IMO it’d be broadly adopted with fewer Qs now.’

It’s important to note that while these concerns are raised, many of the key opinion leaders still view the CROWN results as very positive overall, with Dr. West calling the results ‘truly remarkable’ and  Newsom-Davis referring to lorlatinib as ‘Clearly the most effective 1L ALK TKI.’”

Source: Brian Shields/LinkedIn